Dimethyl fumarate (DMF) is a fumaric acid ester registered for the treatment of relapsing‐
remitting multiple sclerosis (RRMS). It induces protein succination leading to inactivation of …

Dimethyl fumarate (DMF) is an antioxidative and anti-inflammatory drug approved for
treatment of multiple sclerosis and psoriasis; however, beneficial effects of DMF have also …

Dimethyl fumarate (DMF) is an FDA-approved drug for the treatment of psoriasis and
multiple sclerosis. DMF is known to stabilize the transcription factor Nrf2, which in turn …

Multiple sclerosis (MS) shares an immune-mediated origin with psoriasis. Long-term safety
and efficacy data generated in Europe from usage of fumaric acid formulations in the latter …

Several drugs have been approved for treatment of multiple sclerosis (MS). Dimethyl
fumarate (DMF) is utilized as an oral drug to treat this disease and is proven to be potent …

Dimethyl fumarate (DMF) is an effective treatment option for relapsing–remitting multiple
sclerosis (MS), but its therapeutic mechanism of action has not been fully elucidated. A …

Aims: Gastro-resistant dimethyl fumarate (DMF) is an oral therapeutic indicated for the
treatment of relapsing multiple sclerosis. Recent data suggest that a primary …

Background: Delayed-release dimethyl fumarate (DMF) is an approved oral treatment for
relapsing forms of multiple sclerosis (MS). Preclinical studies demonstrated that DMF …

Dimethyl fumarate (Tecfidera®) is a novel oral therapy that has recently been approved for
the treatment of relapsing forms of multiple sclerosis (MS) and relapsing-remitting MS …

Dimethyl fumarate (DMF), a fumaric acid ester, is a new orally available disease-modifying
agent that was recently approved by the US FDA and the EMA for the management of …